- Home
- PPL vs BIIB Comparison
PPL vs BIIB Comparison
Compare PPL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPL
- BIIB
- Stock Information
- Founded
- PPL 1920
- BIIB 1978
- Country
- PPL United States
- BIIB United States
- Employees
- PPL N/A
- BIIB N/A
- Industry
- PPL Electric Utilities: Central
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- PPL Utilities
- BIIB Health Care
- Exchange
- PPL Nasdaq
- BIIB Nasdaq
- Market Cap
- PPL 23.8B
- BIIB 25.1B
- IPO Year
- PPL N/A
- BIIB 1991
- Fundamental
- Price
- PPL $32.60
- BIIB $149.02
- Analyst Decision
- PPL Buy
- BIIB Buy
- Analyst Count
- PPL 12
- BIIB 26
- Target Price
- PPL $35.58
- BIIB $248.00
- AVG Volume (30 Days)
- PPL 4.0M
- BIIB 1.6M
- Earning Date
- PPL 02-14-2025
- BIIB 02-11-2025
- Dividend Yield
- PPL 3.17%
- BIIB N/A
- EPS Growth
- PPL 1.20
- BIIB 10.05
- EPS
- PPL 1.11
- BIIB 11.06
- Revenue
- PPL $8,282,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- PPL $0.66
- BIIB N/A
- Revenue Next Year
- PPL $0.80
- BIIB N/A
- P/E Ratio
- PPL $29.36
- BIIB $13.47
- Revenue Growth
- PPL N/A
- BIIB N/A
- 52 Week Low
- PPL $25.35
- BIIB $145.07
- 52 Week High
- PPL $35.15
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- PPL 45.12
- BIIB 32.44
- Support Level
- PPL $31.52
- BIIB $145.07
- Resistance Level
- PPL $32.78
- BIIB $149.92
- Average True Range (ATR)
- PPL 0.51
- BIIB 3.81
- MACD
- PPL -0.10
- BIIB 0.05
- Stochastic Oscillator
- PPL 38.16
- BIIB 22.51
About PPL PPL Corporation
PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. LG&E and KU are involved in regulated electricity generation, transmission, and distribution in Kentucky. The Kentucky utilities also serve gas customers. Rhode Island Energy operates electric and gas utilities in Rhode Island.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.